Effectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: A case-series

References

• Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20(1):1–16.
   PubMed Web of Science ®Google Scholar
• Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42.
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol. 2012;8(6):348–57.
   PubMed Web of Science ®Google Scholar
• Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013;369(11):1035–45.
   PubMed Web of Science ®Google Scholar
• Ferri C, Sebastiani M, Antonelli A, Colaci M, Manfredi A, Giuggioli D. Current treatment of hepatitis C-associated rheumatic diseases. Arthritis Res Ther. 2012;14(3):215.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Munoz S, Medina F, Jara LJ, Rosas J, Calvo-Alen J. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol. 2009;36(7):1442–8.
   PubMed Web of Science ®Google Scholar
• Su FH, Wu CS, Sung FC, Chang SN, Su CT, Shieh YH, et al. Chronic hepatitis C virus infection is associated with the development of rheumatoid arthritis: a nationwide population-based study in Taiwan. PLoS One. 2014;9(11):e113579.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Commarmond C, Sadoun D, Desbois AC. Hepatitis C virus infection and rheumatic diseases: the impact of direct-acting antiviral agents. Rheum Dis Clin North Am. 2017;43(1):123–32.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010;69(1):43–7.
   PubMed Web of Science ®Google Scholar
• Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol. 2000;18(3):363–8.
   PubMed Web of Science ®Google Scholar
• Burton MJ, Curtis JR, Yang S, Chen L, Singh JA, Mikuls TR, et al. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis C virus infection. J Rheumatol. 2017;44(5):565–70.
   PubMed Web of Science ®Google Scholar
• Liao TL, Hsieh SL, Chen YM, Chen HH, Liu HJ, Lee HC, et al. Rituximab may cause increased hepatitis C virus viremia in rheumatoid arthritis patients through declining exosomal microRNA-155. Arthritis Rheumatol. 2018;70(8):1209–19.
   PubMed Web of Science ®Google Scholar
• Chen YM, Chen HH, Chen YH, Hsieh TY, Hsieh CW, Hung WT, et al. A comparison of safety profiles of tumour necrosis factor alpha inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C. Ann Rheum Dis. 2015;74(3):626–7.
   PubMed Web of Science ®Google Scholar
• Mori N, Imamura M, Takaki S, Araki T, Hayes NC, Aisaka Y, et al. Hepatitis C virus (HCV) reactivation caused by steroid therapy for dermatomyositis. Intern Med. 2014;53(23):2689–93.
   PubMed Web of Science ®Google Scholar
• Gandhi NP, Manadan AM, Block JA. Retrospective study of patients on etanercept therapy for rheumatic diseases in patients with chronic hepatitis C virus. J Clin Rheumatol. 2017;23(5):252–7.
   PubMed Web of Science ®Google Scholar
• Yoshiji S, Takahashi K, Sawada K, Mishima M, Eso Y, Morita M, et al. Accelerated progression of hepatocellular carcinoma during immunosuppressive therapy with abatacept for rheumatoid arthritis. Intern Med. 2019;58(1):67–71.
   PubMed Web of Science ®Google Scholar
• Patel R, Mikuls TR, Richards JS, Kerr G, Cannon GW, Baker JF. Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection. Arthritis Care Res (Hoboken). 2015;67(4):467–74.
   PubMed Web of Science ®Google Scholar
• Baumert TF, Berg T, Lim JK, Nelson DR. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology. 2019;156(2):431–45.
   PubMed Web of Science ®Google Scholar
• Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Ther Adv Gastroenterol. 2015;8(5):298–312.
   PubMed Web of Science ®Google Scholar
• Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453–64.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Zignego AL, Ferri C, Brito-Zeron P, Retamozo S, Casato M, et al. Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol. 2017;66(6):1282–99.
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Milazzo L, Atzeni F, Vacchi C, Manfredi A, Quartuccio L, et al. Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. Mod Rheumatol. 2019. doi:10.1080/14397595.2018.1558918.
   PubMed Web of Science ®Google Scholar
• Kohla M, Iwata S, Ea R, Keyhan S, Taylor R, Yu MC, et al. Histological versus clinical cirrhosis in chronic hepatitis C: does race/ethnicity really matter? Dig Dis Sci. 2012;57(3):771–6.
   PubMed Web of Science ®Google Scholar
• Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646–9.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25.
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573–86.
   PubMed Web of Science ®Google Scholar
• Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404–13.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1–25.
   PubMed Web of Science ®Google Scholar
• Koga T, Kawashiri SY, Nakao K, Kawakami A. Successful ledipasvir + sofosbuvir treatment of active synovitis in a rheumatoid arthritis patient with hepatitis C virus-related mixed cryoglobulinemia. Mod Rheumatol. 2017;27(5):917–8.
   PubMed Web of Science ®Google Scholar
• Enomoto M, Tateishi C, Tsuruta D, Tamori A, Kawada N. Remission of psoriasis after treatment of chronic hepatitis C virus infection with direct-acting antivirals. Ann Intern Med. 2018;168(9):678–80.
   PubMed Web of Science ®Google Scholar
• Heppt F, Sticherling M. Psoriasis as a manifestation of an immune reconstitution in two patients with hepatitis C treated with ledipasvir/sofosbuvir. Acta Derm Venerol. 2017;97(4):526–7.
   PubMed Web of Science ®Google Scholar
• Damiani G, Franchi C, Pigatto P, Altomare A, Pacifico A, Petrou S, et al. Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new direct-acting antiviral agents. World J Hepatol. 2018;10(2):329–36.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Fujieda Y, Yasuda S, Nakai M, Atsumi T. Remission of nephrotic syndrome after therapy for chronic hepatitis C virus infection in a patient with systemic lupus erythematosus. Ann Intern Med. 2018;169(5):352–3.
   PubMed Web of Science ®Google Scholar
• Shahini E, Iannone A, Romagno D, Armandi A, Carparelli S, Principi M, et al. Clinical relevance of serum non-organ-specific antibodies in patients with HCV infection receiving direct-acting antiviral therapy. Aliment Pharmacol Ther. 2018;48(10):1138–45.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Garrido M, Pol S, Desbois AC, Costopoulos M, Le Garff-Tavernier M, et al. Direct-acting antiviral therapy restores immune tolerance to patients with hepatitis C virus-induced cryoglobulinemia vasculitis. Gastroenterology. 2017;152(8):2052–2062.
   PubMed Web of Science ®Google Scholar
• Ray RB, Ray R. Hepatitis C virus manipulates humans as its favorite host for a long-term relationship. Hepatology. 2019;69(2):889–900.
   PubMed Web of Science ®Google Scholar
• Sun J, Rajsbaum R, Yi M. Immune and non-immune responses to hepatitis C virus infection. World J Gastroenterol. 2015;21(38):10739–48.
   PubMed Web of Science ®Google Scholar
• Werner JM, Adenugba A, Protzer U. Immune reconstitution after HCV clearance with direct antiviral agents: potential consequences for patients with HCC? Transplantation. 2017;101(5):904–9.
   PubMed Web of Science ®Google Scholar
• Urbanowicz A, Zagożdżon R, Ciszek M. Modulation of the immune system in chronic hepatitis C and during antiviral interferon-free therapy. Arch Immunol Ther Exp. 2019;67(2):79–88.
   PubMed Web of Science ®Google Scholar
• Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals. Expert Opin Drug Saf. 2017;16(6):651–72.
   PubMed Web of Science ®Google Scholar
• Lin SY, Chen TC, Lu PL, Lin CY, Lin WR, Yang YH, et al. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan. BMC Infect Dis. 2014;14(1):705.
   PubMedGoogle Scholar
• de Oliveira Uehara SN, Emori CT, Perez RM, Mendes-Correa MCJ, de Souza Paiva Ferreira A, de Castro Amaral Feldner AC, et al. High incidence of tuberculosis in patients treated for hepatitis C chronic infection. Braz J Infect Dis. 2016;20(2):205–9.
   PubMed Web of Science ®Google Scholar
• Ballester-Ferre MP, Martinez F, Garcia-Gimeno N, Mora F, Serra MA. Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin. World J Hepatol. 2017;9:161–6.
   PubMed Web of Science ®Google Scholar
• Macias J, Tellez F, Rivero-Juarez A, Palacios R, Morano LE, Merino D, et al. Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients. J Viral Hepat. 2019;26:48–54.
   PubMed Web of Science ®Google Scholar
• Marocco R, Lichtner M, Tieghi T, Pozzetto I, Mastroianni CM. Herpes virus reactivation after initiation of interferon-free antiviral agents in HIV-HCV-coinfected subjects: a new immune restoration disease? Antivir Ther. 2016;21(8):739–42.
   PubMed Web of Science ®Google Scholar
• Perello MC, Fernandez-Carrillo C, Londono MC, Arias-Loste T, Hernandez-Conde M, Llerena S, et al. Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2016;14:1662–6e1.
   PubMed Web of Science ®Google Scholar
• Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37(4):283–94.
   PubMed Web of Science ®Google Scholar